Genprex announces registered direct offering of up to $10M

Genprex (GNPX) announced that it has entered into definitive agreements for the issuance and sale of 377,780 shares of common stock at a purchase price of $9.00 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the company will issue unregistered short-term warrants to purchase an aggregate of up to 755,560 shares of common stock at an exercise price of $8.75 per share that will be immediately exercisable upon issuance and will expire twenty-four months from the effective date of a registration statement registering for resale the shares of common stock underlying the warrants. The closing of the offering is expected to occur on or about October 29, 2025, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to the company from the offering are expected to be approximately $3.4M before deducting placement agent fees and other offering expenses payable by the company. The potential additional gross proceeds to the company from the short-term warrants, if fully-exercised on a cash basis, will be approximately $6.6M.